ACADIA PHARMACEUTICALS INC.
Ownership & governance
Executives 5Directors 9Avg age 58Avg tenure 6.2y
CA
Catherine Adams
Chief Executive Officer
Age 55Since 2024-09-19Profile →
+13
Executives5
CA
Catherine Adams→
Chief Executive Officer
Age 55Since 2024-09-19
MS
Mark Schneyer→
Director of Finance/CFO
Age 52Since 2021-09-09
SC
Scott Cenci→
Chief Tech/Sci/R&D Officer
—Since 2025-08-03
ET
Elizabeth Thompson→
Chief Tech/Sci/R&D Officer
Age 51Since 2024-04-01
SP
Sanjeev Pathak→
Chief Tech/Sci/R&D Officer
—Since 2021-02-28
Board of directors9
LB
Laura Brege→
Director/Board Member
Age 68Since 2008-04-30
SB
Stephen Biggar→
Chairman
Age 55Since 2016-06-09
EH
Edmund Harrigan→
Director/Board Member
Age 73Since 2015-11-24
JB
Julian Baker→
Director/Board Member
Age 59Since 2015-12-10
JD
James Daly→
Director/Board Member
Age 64Since 2016-01-10
EG
Elizabeth Garofalo→
Director/Board Member
Age 68Since 2020-09-28
AN
Adora Ndu→
Director/Board Member
Age 45Since 2022-10-09
CA
Catherine Adams→
Director/Board Member
Age 55Since 2024-09-19
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Baker Bros. Advisors LP | 25.15 % | 43,061,944 |
| Baker Bros. Advisors LP | 25.05 % | 42,896,690 |
| BlackRock Advisors LLC | 11.7 % | 20,028,722 |
| Vanguard Portfolio Management LLC | 5.064 % | 8,671,645 |
| STATE STREET CORPORATION | 4.866 % | 8,332,771 |
Catalog · 2026-07-09
Registry officers14
| Name | Role | Since | Shares |
|---|---|---|---|
| Catherine Adams | Chief Executive Officer | 2024-09-19 | - |
| Elizabeth Thompson | Chief Tech/Sci/R&D Officer | 2024-04-01 | - |
| Mark Schneyer | Director of Finance/CFO | 2021-09-09 | - |
| Sanjeev Pathak | Chief Tech/Sci/R&D Officer | 2021-02-28 | - |
| Scott Cenci | Chief Tech/Sci/R&D Officer | 2025-08-03 | - |
| Stephen Biggar | Chairman | 2016-06-09 | - |
| Adora Ndu | Director/Board Member | 2022-10-09 | - |
| Catherine Adams | Director/Board Member | 2024-09-19 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 30.58Range 17–37Analysts 19
17Mean 30.5837
- Strong buy 4
- Buy 10
- Hold 5
- Sell 1
Broker actions40 of 341
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| UBS | Downgrade | Neutral | 23 | 2026-10-13 |
| RBC Capital | Maintained | Outperform | 36 | 2026-10-08 |
| Deutsche Bank | Maintained | Buy | 31 | 2026-09-25 |
| HC Wainwright & Co. | Maintained | Buy | 33 | 2026-09-25 |
| Citizens | Maintained | Market Outperform | 33 | 2026-09-25 |
| BMO Capital | Maintained | Outperform | 34 | 2026-09-25 |
| Needham | Maintained | Buy | 35 | 2026-09-25 |
| Citigroup | Maintained | Buy | 33 | 2026-09-24 |
| Needham | Reiterated | Buy | 41 | 2026-09-24 |
| Deutsche Bank | Maintained | Buy | 38 | 2026-08-25 |
| Morgan Stanley | Maintained | Equal-Weight | 28 | 2026-08-25 |
| Citigroup | Maintained | Buy | 40 | 2026-08-25 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.